REG - Convatec Group PLC - Director Declaration

ConvaTecAnnouncement

01/08/2024 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240801:nRSA7954Ya&default-theme=true

RNS Number : 7954Y  Convatec Group PLC  01 August 2024

1 August 2024

Convatec Group Plc

("Convatec" or "the Company")

Convatec Director Declaration

The Company announces that effective today Brian May, a non-executive director
of the Company, serves as a director of Ferguson Enterprises Inc., which is
the new ultimate parent company of the Ferguson plc group, in place of
Ferguson plc, pursuant to a corporate reorganisation. Ferguson Enterprises
Inc. is a publicly quoted company with a primary listing on the New York Stock
Exchange (NYSE: FERG) effective from 1 August 2024 and a secondary listing on
the equity shares (international commercial companies secondary listing)
segment of the Official List of the Financial Conduct Authority and is
admitted to trading on the London Stock Exchange (LSE:FERG). In connection
with the reorganisation, Brian May ceased to be a non-executive director of
Ferguson plc.

 

This announcement is made in accordance with UK Listing Rule 6.4.9R.

 

Enquiries

James Kerton, EVP, General Counsel & Company Secretary, Convatec

James.kerton@convatec.com (mailto:James.kerton@convatec.com)

+44(0)7827 036059

 

                 
                        

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in advanced
wound care, ostomy care, continence and critical care, and infusion care. With
around 10,000 colleagues, we provide our products and services in almost 100
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Group revenues in 2023
were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more about Convatec, please visit
http://www.convatecgroup.com (http://www.convatecgroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNUPUBURUPCUBG